Shanghai Bio-heart FY26 H1 net loss widens to RMB 33.23 million; revenue falls 31.08% to RMB 14.38 million

• Shanghai Bio-heart posted a net loss of RMB 33.23 million, widening from RMB 26.73 million a year earlier.
• Revenue fell to RMB 14.38 million from RMB 20.86 million, while gross profit slipped to RMB 6.72 million from RMB 9.7 million.
• Research and development expenses climbed to RMB 35.83 million from RMB 20.09 million, driven by higher third-party contracting costs.
• Other income and gains rose to RMB 9.69 million from RMB 764,000, mainly on RMB 6.5 million of government grants.
• Bioheart bioabsorbable drug-eluting stents won NMPA clearance; Iberis RDN system had market-access approvals in 23 countries, with reimbursement in six.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bio-heart Biological Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300951), on August 26, 2026, and is solely responsible for the information contained therein.